THE APEX TIMES
Across 456 large U.S. fund managers that disclosed 13F filings for the quarter ended Sept. 30, 10 reported new buying in Eli Lilly, while 18 reported selling. The mixed flow highlights how diversified institutional portfolios can reach different conclusions even during the same period.
Institutional money flow into Eli Lilly (LLY) looked split in the latest wave of 13F disclosures, which track equity holdings reported by large investment managers to U.S. regulators. In an analysis published Monday by Yahoo Finance, 456 big funds that filed for the quarter ended Sept. 30 showed 10 buying Eli Lilly and 18 selling it, meaning more managers reported trimming than adding during that specific reporting window.
The article also spotlighted Cathie Wood’s ARK investment franchise and labeled it among the buyers. According to the same write-up, Cathie Wood and nine other large funds were reported as part of the group that increased exposure to Eli Lilly over the quarter, while a larger set of managers opted to reduce positions.
A 13F is a quarterly report in which investment managers with sufficiently large portfolios disclose their holdings in many U.S.-listed stocks. It is widely used as a proxy for institutional sentiment, but it does not capture trades in real time, and it does not reveal position sizes in the way some investors might expect. It also reflects portfolios on the report date, which can differ from intraperiod trading behavior.
While the Yahoo Finance summary does not break out the size of increases or the extent of reductions, the headline numbers still suggest that Eli Lilly was a stock with active attention on both sides. More than half of the covered managers did not report a buying or selling change in that quarter’s filing data used in the analysis, leaving the reported divergence concentrated among the managers that actively added or actively pared.
Eli Lilly is one of the largest companies in U.S. healthcare, with a product pipeline that has drawn major institutional focus in recent years. In such an environment, 13F buying and selling can reflect a range of factors, including portfolio rebalancing, risk management, and different time horizons for therapeutics demand and regulatory outcomes. The same quarter can therefore produce both additions and trims even if the underlying business outlook is broadly understood.
The most important limitation is what the filings do not explain. The Yahoo Finance post summarized the count of funds that reported buying versus selling but did not provide detailed rationale for each manager, and it did not disclose whether trades were driven by specific catalysts such as clinical trial updates, manufacturing developments, reimbursement expectations, or valuation views. Without that context, it is not possible to determine whether the buying or the selling was in response to a particular Eli Lilly event during the quarter.
Looking ahead, investors and analysts typically watch for whether institutional flows reaccelerate in subsequent quarters and whether managers that trimmed in this window return as new data emerges. More directly, the next steps are likely to include additional 13F cycles and, separately, company-specific updates that can shift consensus about growth and margins.
For readers interpreting the quarter-ended Sept. 30 snapshot, the key takeaway is not that Eli Lilly was universally bought or universally sold. Instead, the pattern described by the analysis points to a market where institutional views diverged, with more managers reporting sells than buys during that period.
The beverage alcohol maker said an executive will discuss company developments at the 2026 gathering of consumer and retail investors.
The alternative asset manager said its president and chief operating officer is scheduled to present at the Goldman Sachs event on Wednesday, according to a new announcement filed through market channels.
UnitedHealth slid after the Centers for Medicare and Medicaid Services proposed expanding Medicare Advantage audits and potentially recovering plan overpayments dating back to 2018, a move other managed-care and pharmacy-linked insurers also faced.
The tech investor argues that regulatory or compliance pressure may force NVIDIA’s latest GPUs to include buyer verification checks that amount to a biometric-style “kill switch,” aiming to deter resale or diversion to restricted end users.
A recent market note argues that Alphabet’s platform could offer better five-year stock upside than Amazon, pointing to how AI is being embedded into cloud products and distribution. The piece stops short of providing new, primary data on near-term earnings.
Ahead of its late-Tuesday results, Nvidia is set to update investors on performance for its fiscal third quarter, a key checkpoint for demand trends in AI-linked data center spending.
In results for its third quarter of fiscal 2027, NVIDIA said revenue rose more than twofold year over year, with data center revenue accounting for nearly all of the company’s growth.
Broad-market indexes slipped on Tuesday, with Nvidia’s upcoming earnings acting as a key weight on sentiment, according to Yahoo Finance.
A new Yahoo Finance comparison frames Eaton’s electrical exposure as a lever for data-center growth, while casting Honeywell’s strategy shift toward automation as a tradeoff that could change how investors view risk in 2027.
In a Q3 2026 earnings call posted by Yahoo Finance, Home Depot highlighted a CEO handoff and lowered growth expectations tied to its SRS metric, indicating a more cautious near-term view of demand.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...